Overview

A Phase 3 Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 in patients with essential hypertension
Phase:
Phase 3
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited